Developer docs
API playgroundTry for free, no card

Search company profiles

Sherlock Biosciences

Full company profile

uuid0000b3p

Namestring
Sherlock Biosciences
Legal namestring
Sherlock Biosciences, Inc.
Websiteurl
sherlock.bio
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Sherlock Biosciences is a CRISPR-based molecular diagnostics company that develops rapid, equipment-minimal tests for detecting DNA and RNA targets in clinical and consumer settings. Its core technology is the SHERLOCK platform, built around the Cas13 enzyme and operated under an exclusive license from the Broad Institute, which enables programmable nucleic acid detection outside specialized laboratory infrastructure. The company's product portfolio includes STOPCovid, which received FDA Emergency Use Authorization in 2020 as the first FDA-authorized CRISPR diagnostic test, the commercially launched SHERLOCK CRISPR Diagnostic Kit (2025), and a pipeline of rapid molecular diagnostic devices targeting sub-10-minute results for home and point-of-care use. Sherlock pursued a dual go-to-market model addressing healthcare providers requiring fast turnaround molecular testing and individual consumers seeking accessible at-home diagnostics, with stated application expansion into agriculture and environmental monitoring.

The company was co-founded in 2017 by MIT researchers Omar Abudayyeh and Jonathan Gootenberg alongside a high-profile scientific advisory group including Feng Zhang, David R. Walt, Jim Collins, Pardis Sabeti, and Todd Golub. It raised approximately $111 million in disclosed funding across rounds led by Northpond Ventures (Series A, 2019), Novalis LifeSciences (Series B, 2022), with participation from Bill & Melinda Gates Foundation, Illumina Ventures, Catalio Capital Management, and others. Revenue mechanics consisted of diagnostic product sales and potential licensing royalties from the Broad Institute platform. In February 2023 the company acquired Sense Biodetection to broaden its instrument-free rapid diagnostic capabilities, and in December 2024 Sherlock was itself acquired by OraSure Technologies (NASDAQ: OSUR) to integrate CRISPR molecular diagnostics into OraSure's point-of-care and home STI testing portfolio.

Short descriptiontext

Sherlock Biosciences is a CRISPR-based molecular diagnostics company developing rapid, equipment-minimal DNA and RNA detection tests for clinical and consumer markets. Now a subsidiary of OraSure Technologies following its December 2024 acquisition.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
CRISPR diagnostics, molecular diagnostics, infectious disease testing, point-of-care testing, DNA RNA detection
Industry3 codes
PRIMARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
NAICS code3 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical and Diagnostic Laboratories6215
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Molecular Diagnostics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Diagnostic Products
TypeHardware Sales
Description

Revenue generated from the sale of rapid molecular diagnostic devices and tests for clinical and consumer markets, including COVID-19 testing and STI testing platforms.

medcitynews.com
2Technology Licensing
TypeLicensing Royalties
Description

Exclusive license arrangement with Broad Institute for CRISPR platform technology, potentially generating licensing royalties from the proprietary SHERLOCK diagnostics platform.

finance.yahoo.com
Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Sherlock Biosciences develops CRISPR-based molecular diagnostic kits and devices using the Cas13 enzyme for rapid DNA and RNA target detection. Its SHERLOCK platform powers multiple diagnostic offerings, including the FDA Emergency Use Authorized STOPCovid test, designed for rapid results in less than 10 minutes with minimal equipment requirements for point-of-care and home-use applications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Results delivered in less than 10 minutes
+1 more record
Product overview1 text field

Sherlock Biosciences operates as a CRISPR-based molecular diagnostics company with a platform-plus-products architecture. The core SHERLOCK CRISPR platform (with exclusive license from Broad Institute) powers multiple offerings including the FDA-authorized STOPCovid test and the commercialized SHERLOCK CRISPR Diagnostic Kit for DNA/RNA detection. The company is developing rapid molecular diagnostic devices for home use targeting both clinical and consumer markets. The technology portfolio spans infectious disease diagnostics (COVID-19, STIs) with applications expanding to agriculture and environmental monitoring.

Product and service3 records
1SHERLOCK CRISPR Diagnostic Kit
CategoryMolecular Diagnostics
Description

A CRISPR-based molecular diagnostic kit utilizing the Cas13 enzyme for detection of DNA and RNA targets, offering rapid, accurate disease diagnostics with minimal equipment requirements for clinical and consumer markets.

2STOPCovid
CategoryMolecular Diagnostics
Description

FDA Emergency Use Authorized CRISPR-based COVID-19 diagnostic test developed by MIT co-founders. Designed for rapid, easy use enabling detection of SARS-CoV-2 virus from patient samples outside specialized laboratory settings.

3Rapid Molecular Diagnostic Devices for Home Use
CategoryMolecular Diagnostics
Description

Next-generation rapid molecular diagnostic devices leveraging CRISPR and synthetic biology technologies. Target results in less than 10 minutes for both clinical and consumer markets with home-use capability.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-03-08
Description

Exclusive licensing agreement for CRISPR platform technology used in SHERLOCK diagnostics. This is a foundational technology partnership that enables Sherlock Biosciences to commercialize CRISPR-based molecular diagnostic products.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Acquired Sherlock Biosciences in December 2024 to integrate Sherlock's molecular diagnostics platform for home testing of sexually transmitted infections. The acquisition expands OraSure's point-of-care testing development capabilities.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Mammoth Biosciences is the closest direct competitor in CRISPR-based molecular diagnostics, co-founded by Jennifer Doudna. It develops the DETECTR platform using Cas12 and Cas13 enzymes for DNA/RNA detection across infectious disease and oncology — directly overlapping Sherlock's SHERLOCK platform in technology, modality, and target customers.

TypeBroad incumbent
Description

Cepheid, a Danaher subsidiary, is the established leader in rapid molecular diagnostics with its GeneXpert system deployed across hospitals and reference labs globally. It competes with Sherlock in clinical molecular diagnostic workflows but operates at much larger scale and across a broader menu of indications.

TypeBroad incumbent
Description

BioFire, a subsidiary of bioMérieux, markets the FilmArray syndromic molecular diagnostic panels widely used in clinical settings. It represents a broad incumbent in rapid molecular diagnostics with established hospital placement that competes for the same clinical customer set as Sherlock's clinical-channel products.

TypeBroad incumbent
Description

Hologic's Panther Fusion system provides high-throughput molecular diagnostics for infectious disease and women's health, including STI testing — directly overlapping with the STI testing use case Sherlock is pursuing through OraSure. It is a broad incumbent with established relationships in the same hospital and reference lab channels.

5Abbott Diagnostics
TypeBroad incumbent
Description

Abbott offers ID NOW, a rapid molecular point-of-care platform, alongside its broader Alinity diagnostics franchise. It is a broad incumbent competing across both clinical molecular diagnostics and rapid point-of-care testing where Sherlock's STOPCovid and home-use devices are positioned.

TypeBroad incumbent
Description

QIAGEN provides sample-preparation and molecular diagnostic testing solutions used widely in clinical and research labs. It serves as an incumbent in the broader molecular diagnostics workflow and represents a potential commercialization partner or competitor for Sherlock's platform depending on direction.

7Cue Health
TypeEmerging player
Description

Cue Health developed a connected at-home molecular diagnostic cartridge platform initially for COVID-19 and expanding into other respiratory and sexual health indications. It competes directly with Sherlock's home-use rapid molecular diagnostic positioning and represents a comparable consumer health go-to-market model.

TypeEmerging player
Description

Detect is developing CRISPR-based at-home molecular diagnostic tests for infectious disease, including a CRISPR-Cas12a-based platform. It is an emerging player directly comparable to Sherlock's consumer molecular diagnostic positioning with overlapping chemistry and use-case focus.

TypeEmerging player
Description

binx health offers rapid molecular diagnostic testing for sexually transmitted infections through both clinical and at-home channels. It directly competes with Sherlock's planned STI testing expansion through OraSure, with comparable platform strategy targeting the same customer segment.

TypeBroad incumbent
Description

Roche Diagnostics operates the cobas molecular diagnostic franchise, which is one of the largest installed bases of high-throughput molecular testing globally. It is a broad incumbent that competes for the same clinical and reference lab molecular diagnostic customers Sherlock targets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sherlock Biosciences

Molecular Diagnosticssherlock.bio

Sherlock Biosciences is a CRISPR-based molecular diagnostics company developing rapid, equipment-minimal DNA and RNA detection tests for clinical and consumer markets. Now a subsidiary of OraSure Technologies following its December 2024 acquisition.

What Sherlock Biosciences does

Sherlock Biosciences is a CRISPR-based molecular diagnostics company that develops rapid, equipment-minimal tests for detecting DNA and RNA targets in clinical and consumer settings. Its core technology is the SHERLOCK platform, built around the Cas13 enzyme and operated under an exclusive license from the Broad Institute, which enables programmable nucleic acid detection outside specialized laboratory infrastructure. The company's product portfolio includes STOPCovid, which received FDA Emergency Use Authorization in 2020 as the first FDA-authorized CRISPR diagnostic test, the commercially launched SHERLOCK CRISPR Diagnostic Kit (2025), and a pipeline of rapid molecular diagnostic devices targeting sub-10-minute results for home and point-of-care use. Sherlock pursued a dual go-to-market model addressing healthcare providers requiring fast turnaround molecular testing and individual consumers seeking accessible at-home diagnostics, with stated application expansion into agriculture and environmental monitoring.

The company was co-founded in 2017 by MIT researchers Omar Abudayyeh and Jonathan Gootenberg alongside a high-profile scientific advisory group including Feng Zhang, David R. Walt, Jim Collins, Pardis Sabeti, and Todd Golub. It raised approximately $111 million in disclosed funding across rounds led by Northpond Ventures (Series A, 2019), Novalis LifeSciences (Series B, 2022), with participation from Bill & Melinda Gates Foundation, Illumina Ventures, Catalio Capital Management, and others. Revenue mechanics consisted of diagnostic product sales and potential licensing royalties from the Broad Institute platform. In February 2023 the company acquired Sense Biodetection to broaden its instrument-free rapid diagnostic capabilities, and in December 2024 Sherlock was itself acquired by OraSure Technologies (NASDAQ: OSUR) to integrate CRISPR molecular diagnostics into OraSure's point-of-care and home STI testing portfolio.

Sherlock Biosciences firmographics

Firmographics
Name
Sherlock Biosciences
Legal name
Sherlock Biosciences, Inc.
Website
https://sherlock.bio
Company type
Private
Founded year
2019
Operating status
Acquired
Headcount range
11–50 employees
Short description
Sherlock Biosciences is a CRISPR-based molecular diagnostics company developing rapid, equipment-minimal DNA and RNA detection tests for clinical and consumer markets. Now a subsidiary of OraSure Technologies following its December 2024 acquisition.
Ownership category
akta.pro rank

Sherlock Biosciences industry classification

Industry
Product category
Molecular Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (6215)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)

Keywords

  • CRISPR diagnostics
  • Molecular diagnostics
  • Infectious disease testing
  • Point-of-care testing
  • DNA RNA detection

Where Sherlock Biosciences is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Sherlock Biosciences business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Diagnostic Products: Revenue generated from the sale of rapid molecular diagnostic devices and tests for clinical and consumer markets, including COVID-19 testing and STI testing platforms.
  2. Technology Licensing: Exclusive license arrangement with Broad Institute for CRISPR platform technology, potentially generating licensing royalties from the proprietary SHERLOCK diagnostics platform.

Go-to-market motion1 record

Sherlock Biosciences product offering

Product offering

Core offering

Sherlock Biosciences develops CRISPR-based molecular diagnostic kits and devices using the Cas13 enzyme for rapid DNA and RNA target detection. Its SHERLOCK platform powers multiple diagnostic offerings, including the FDA Emergency Use Authorized STOPCovid test, designed for rapid results in less than 10 minutes with minimal equipment requirements for point-of-care and home-use applications.

Product overview

Sherlock Biosciences operates as a CRISPR-based molecular diagnostics company with a platform-plus-products architecture. The core SHERLOCK CRISPR platform (with exclusive license from Broad Institute) powers multiple offerings including the FDA-authorized STOPCovid test and the commercialized SHERLOCK CRISPR Diagnostic Kit for DNA/RNA detection. The company is developing rapid molecular diagnostic devices for home use targeting both clinical and consumer markets. The technology portfolio spans infectious disease diagnostics (COVID-19, STIs) with applications expanding to agriculture and environmental monitoring.

Differentiator

Problem solved

Functional benefit

Products and services

  • SHERLOCK CRISPR Diagnostic Kit A CRISPR-based molecular diagnostic kit utilizing the Cas13 enzyme for detection of DNA and RNA targets, offering rapid, accurate disease diagnostics with minimal equipment requirements for clinical and consumer markets.
  • STOPCovid FDA Emergency Use Authorized CRISPR-based COVID-19 diagnostic test developed by MIT co-founders. Designed for rapid, easy use enabling detection of SARS-CoV-2 virus from patient samples outside specialized laboratory settings.
  • Rapid Molecular Diagnostic Devices for Home Use Next-generation rapid molecular diagnostic devices leveraging CRISPR and synthetic biology technologies. Target results in less than 10 minutes for both clinical and consumer markets with home-use capability.

Quantifiable outcome

  • Results delivered in less than 10 minutes
  • +1 more outcomes

Companies that use Sherlock Biosciences

Customer profile

Segments3 records

Ideal customer profiles2 records

Sherlock Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Sherlock Biosciences partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Broad InstitutecoreTechnology or Integration · 8 March 2022Exclusive licensing agreement for CRISPR platform technology used in SHERLOCK diagnostics. This is a foundational technology partnership that enables Sherlock Biosciences to commercialize CRISPR-based molecular diagnostic products.
  • OraSure TechnologiescoreStrategic or Co-development PartnerAcquired Sherlock Biosciences in December 2024 to integrate Sherlock's molecular diagnostics platform for home testing of sexually transmitted infections. The acquisition expands OraSure's point-of-care testing development capabilities.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Sherlock Biosciences competitors and assessment

Company assessment

Direct peers

  • Mammoth Biosciences: Mammoth Biosciences is the closest direct competitor in CRISPR-based molecular diagnostics, co-founded by Jennifer Doudna. It develops the DETECTR platform using Cas12 and Cas13 enzymes for DNA/RNA detection across infectious disease and oncology — directly overlapping Sherlock's SHERLOCK platform in technology, modality, and target customers.

Broad incumbents

  • Cepheid (Danaher): Cepheid, a Danaher subsidiary, is the established leader in rapid molecular diagnostics with its GeneXpert system deployed across hospitals and reference labs globally. It competes with Sherlock in clinical molecular diagnostic workflows but operates at much larger scale and across a broader menu of indications.
  • bioMérieux (BioFire Diagnostics): BioFire, a subsidiary of bioMérieux, markets the FilmArray syndromic molecular diagnostic panels widely used in clinical settings. It represents a broad incumbent in rapid molecular diagnostics with established hospital placement that competes for the same clinical customer set as Sherlock's clinical-channel products.
  • Hologic: Hologic's Panther Fusion system provides high-throughput molecular diagnostics for infectious disease and women's health, including STI testing — directly overlapping with the STI testing use case Sherlock is pursuing through OraSure. It is a broad incumbent with established relationships in the same hospital and reference lab channels.
  • Abbott Diagnostics: Abbott offers ID NOW, a rapid molecular point-of-care platform, alongside its broader Alinity diagnostics franchise. It is a broad incumbent competing across both clinical molecular diagnostics and rapid point-of-care testing where Sherlock's STOPCovid and home-use devices are positioned.
  • QIAGEN: QIAGEN provides sample-preparation and molecular diagnostic testing solutions used widely in clinical and research labs. It serves as an incumbent in the broader molecular diagnostics workflow and represents a potential commercialization partner or competitor for Sherlock's platform depending on direction.
  • Roche Diagnostics: Roche Diagnostics operates the cobas molecular diagnostic franchise, which is one of the largest installed bases of high-throughput molecular testing globally. It is a broad incumbent that competes for the same clinical and reference lab molecular diagnostic customers Sherlock targets.

Emerging players

  • Cue Health: Cue Health developed a connected at-home molecular diagnostic cartridge platform initially for COVID-19 and expanding into other respiratory and sexual health indications. It competes directly with Sherlock's home-use rapid molecular diagnostic positioning and represents a comparable consumer health go-to-market model.
  • Detect (formerly Homodeus): Detect is developing CRISPR-based at-home molecular diagnostic tests for infectious disease, including a CRISPR-Cas12a-based platform. It is an emerging player directly comparable to Sherlock's consumer molecular diagnostic positioning with overlapping chemistry and use-case focus.
  • binx health: binx health offers rapid molecular diagnostic testing for sexually transmitted infections through both clinical and at-home channels. It directly competes with Sherlock's planned STI testing expansion through OraSure, with comparable platform strategy targeting the same customer segment.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Sherlock Biosciences social profiles

Digital presence

Sherlock Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sherlock Biosciences leadership team

Management profile

Number of profiles

Profiles14 records

Sherlock Biosciences funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sherlock Biosciences M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sherlock Biosciences

What does Sherlock Biosciences do?

Sherlock Biosciences develops CRISPR-based molecular diagnostic kits and devices using the Cas13 enzyme for rapid DNA and RNA target detection. Its SHERLOCK platform powers multiple diagnostic offerings, including the FDA Emergency Use Authorized STOPCovid test, designed for rapid results in less than 10 minutes with minimal equipment requirements for point-of-care and home-use applications.

Is Sherlock Biosciences a public or private company?

Sherlock Biosciences is a private company. It is classified as corporate owned and is currently acquired.

When was Sherlock Biosciences founded?

Sherlock Biosciences was founded in 2019. It employs 11 to 50 people.

Where is Sherlock Biosciences based?

Sherlock Biosciences is headquartered in Boston, United States, in the North America region.

How does Sherlock Biosciences make money?

Two revenue lines are on record. Diagnostic Products are the primary driver. The others are technology Licensing.

Who are Sherlock Biosciences's main competitors?

Mammoth Biosciences is listed as a direct peer. Broad incumbents are Cepheid (Danaher), bioMérieux (BioFire Diagnostics), Hologic, Abbott Diagnostics, QIAGEN and Roche Diagnostics. Emerging players are Cue Health, Detect (formerly Homodeus) and binx health.

Does Sherlock Biosciences have an API?

No public API is recorded for Sherlock Biosciences.

What industry is Sherlock Biosciences in?

Sherlock Biosciences's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD), with a secondary code of HLAAALAA, Molecular Diagnostics (PCR/qPCR, NGS-based assays). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
StartupmagFuse Diagnostics raises £1m led by FSE Group with Cambridge Capital GroupFuse Diagnostics raised £1m in a pre-seed round led by FSE Group with Cambridge Capital Group to commercialise its Flip molecular diagnostics platform. The funding will accelerate assay development and validation across industrial and environmental markets, including food safety, water monitoring, and bioprocessing.openPR.comStructure of the Over The Counter (OTC) Test Market, Emerging Trends, and Key Player AnalysisThe OTC test market is projected to reach $52.01 billion by 2030, growing at a 13.5% CAGR, driven by increased home healthcare adoption, demand for personalized diagnostics, and integration with mobile devices. In December 2024, OraSure Technologies acquired Sherlock Biosciences to integrate Sherlock's molecular diagnostics platform for home testing of sexually transmitted infections. Additionally, UK-based BlueStain Global Ltd launched an MPox virus detection kit in August 2024 that can deliver results within 15 to 30 minutes.openPR.comCRISPR-Based Diagnostics Market to Reach US$ 12.09 Billion by 2033 Driven by Rapid Molecular Testing, Advancements in CRISPR Technologies, and Growing Demand for Point-of-Care DiagnosticsThe global CRISPR-based diagnostics market is projected to grow from US$3.04 billion in 2024 to US$12.09 billion by 2033, representing a compound annual growth rate of 16.7% over the forecast period 2025–2033. Growth is driven by increasing demand for rapid, accurate, and cost-effective diagnostic solutions for infectious diseases, genetic disorders, and point-of-care testing, supported by rising investments in molecular diagnostics, biotechnology research, and precision medicine. Key industry participants including Thermo Fisher Scientific and Danaher Corporation are pursuing strategic expansions and collaborations in CRISPR technologies, while companies such as Sherlock Biosciences, Mammoth Biosciences, and Intellia Therapeutics continue advancing product development and R&D in CRISPR-based detection platforms.openPR.comTrends in Growth, Segment Analysis, and Competitive Strategies Influencing the Sexually Transmitted Infection (STI) and Vaginitis Polymerase Chain Reaction (PCR) Testing MarketThe STI and vaginitis PCR testing market is projected to reach $1.08 billion by 2030, growing at a compound annual growth rate of 9.5%, driven by increasing demand for point-of-care molecular diagnostics and innovations in multiplex PCR technologies. In December 2024, OraSure Technologies acquired Sherlock Biosciences to expand its molecular diagnostics portfolio in sexual health with rapid, self-collected STI testing technology. Thermo Fisher Scientific launched the Applied Biosystems TrueMark STI Select Panel in February 2023, a multiplex real-time PCR assay that simultaneously detects four common STIs.FierceBiotechAltai Capital angles for OraSure board seats and a saleAltai Capital Management, holding a 5.2% stake in OraSure Technologies, is pushing the infectious disease testmaker to explore a full sale of the business while nominating two candidates for election to the board at the upcoming annual meeting. The hedge fund cited OraSure's declining stock price, a 22% fourth-quarter core business decline, and criticized recent investments including $30 million in Sapphiros and at least $25 million toward acquiring Sherlock Biosciences. Altai values OraSure's operating business at $145–241 million for a strategic buyer, representing a 42%–107% premium per share over current trading levels.openPR.comSynthetic Biology Market Is Estimated To Surge Ahead At A Cagr Of 25% From 2025 To 2034Custom Market Insights released a market research report projecting the global synthetic biology market to grow from USD 28.23 billion in 2025 to USD 150.93 billion by 2034, representing a compound annual growth rate of 25% over the forecast period. The report identifies healthcare, agriculture, industrial biotechnology, and environmental applications as key drivers, while noting challenges including high initial costs, regulatory complexities, and lack of standardized protocols. Recent notable developments include Sherlock Biosciences' acquisition of Sense Biodetection in February 2023 and Ginkgo Bioworks' partnership with Sojitz Corporation in May 2024.InsideprecisionmedicineBringing Precision Medicine Into the HomeMultiple medtech and biotech companies are developing at-home and non-invasive diagnostic testing technologies, ranging from continuous glucose monitors to breath-based tests, driven by patient demand for convenience and the COVID-19 pandemic's normalization of home testing. Notable developments include Biolinq's FDA-approved semiconductor-based continuous glucose sensor, OraSure's acquisition of Sherlock Biosciences for expanded STI testing, and Teal Health's FDA-approved vaginal self-collection device for HPV screening. Industry analysts predict the at-home and non-invasive testing markets will grow at compound annual rates of approximately 5% and 9% respectively over the next decade, potentially enabling a shift toward preventive and precision medicine.SynthegoCRISPR Office Hours: First FDA-Authorized Use of CRISPR Diagnostics for COVID-19Researchers at MIT, co-founders of Sherlock Biosciences, received FDA Emergency Use Authorization for their CRISPR-based COVID-19 diagnostic test called STOPCovid. The test is designed for rapid, easy use, enabling detection of the virus from patient samples with a simplified process that can be performed outside of specialized labs.SynthegoSHERLOCK CRISPR Kit: The Next Generation of Diagnostics (with Podcast)Sherlock Biosciences, co-founded by Omar Abudayyeh and Jonathan Gootenberg, developed the SHERLOCK CRISPR diagnostic kit utilizing the Cas13 enzyme for DNA and RNA detection. The technology offers rapid, accurate, and equipment-minimal disease diagnostics and is set to be commercialized soon for use by the general public. The founders plan to expand applications to various fields including health, agriculture, and environmental monitoring.News-MedicalCRISPR-Based Diagnostics: The Future of Disease DetectionSherlock Biosciences, which was acquired by OraSure Technologies in 2024, has initiated a clinical trial for a rapid, over-the-counter CRISPR-based diagnostic test for Chlamydia and Gonorrhea. The PROMISE trial involves 2,500 participants to compare the new molecular test against current PCR standards, with the goal of obtaining FDA approval for widespread use.